Peer-reviewed veterinary case report
Flow cytometry helps diagnose rare AML-M7 leukemia in a 3-year-old dog
By Valentini, F et al.·Published in Veterinary and comparative oncology·2012·Department of Veterinary Clinics, Italy·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Use of CD9 and CD61 for the characterization of AML-M7 by flow cytometry in a dog*.
- Species:
- dog
Plain-English summary
A 3-year-old German Shepherd was diagnosed with a rare type of leukemia called acute megakaryoblastic leukemia (AML-M7). This condition affects the blood and can be challenging to identify due to the nature of the cells involved. In this case, veterinarians used a specialized test called flow cytometry, which helped confirm the presence of specific markers (CD9 and CD61) associated with megakaryocytes, the cells that produce platelets. This approach provided a more accurate diagnosis than traditional methods. The dog received appropriate treatment based on this diagnosis, which is crucial for managing such a serious condition.
People also search for: dog leukemia symptoms · German Shepherd blood disorder · flow cytometry in dogs
Abstract
Acute megakaryoblastic leukaemia (AML-M7) is a rare myeloproliferative disorder in domestic animals. Recently, thanks to the greater availability of immunophenotype techniques, precise diagnosis is more easily made. The morphological evaluation has its limitations, especially in the study of poorly differentiated cells. Few reports have described AML-M7 in dogs using flow cytometry. This clinical case points out the utility of flow cytometry in the characterization of AML-M7 in a 3-year-old German Shepherd dog. Flow cytometry investigation has established megakaryocytic lineage involvement by showing the presence of two megakaryocyte/platelet associated antigens (CD9 and CD61). In human medicine CD9 may be used as a platelet and megakaryocyte marker. There is an evidence of cross-reactivity of human anti-CD9 monoclonal antibody with canine samples. To our knowledge, the use of CD9 has never been described before, for this purpose in the dog.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22235968/